Leon S. Dure, M.D.


ldureProfessor
 

Primary Department Affiliation: Pediatrics and Neurology

Email:
Phone: 205.996.7850
Fax: 205.996.7867

Recent Publications

 

BIOGRAPHICAL SKETCH

NAME

Leon Sebring Dure, IV, MD

eRA COMMONS USER NAME

POSITION TITLE

Professor - Pediatrics, Neurology, and Neurobiology

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

YEAR(s)

FIELD OF STUDY

Rice University, Houston, Texas

BA

1976-1980

Biochemistry

Baylor College of Medicine, Houston, Texas

MD

1980-1984

Medicine

Columbia University, New York

Resident

1984-1986

Pediatrics

Baylor College of Medicine, Houston, Texas

Fellow

1986-1989

Pediatric Neurology

University of Michigan, Ann Arbor, Michigan

Fellow

1989-1991

Neuroscience


A. Positions and Honors

Positions and Employment

1984-1986 Resident in Pediatrics, Babies Hospital, New York, NY

1986-1989 Fellow in Pediatric Neurology, Baylor College of Medicine, Houston, TX

1989-1991 Postdoctoral Fellowship, Department of Neurology, University of Michigan, Ann Arbor, MI

1990-1991 Instructor, Departments of Neurology and Pediatrics, University of Michigan, Ann Arbor, MI

1991-1994 Instructor, Department of Neurology, Harvard Medical School, Boston, MA

1991-1994 Assistant in Neurology, Massachusetts General Hospital, Boston, MA

1994-1998 Assistant Professor of Pediatrics and Neurology, University of Alabama at Birmingham, AL

1997-present Adjunct Professor of Neurobiology, University of Alabama at Birmingham, AL

1998-2004 Associate Professor of Pediatrics (Neurology), University of Alabama at Birmingham

2004-present Professor of Pediatrics (Neurology), University of Alabama at Birmingham

Honors:

1989-1991 Postdoctoral Fellowship, Huntington's Disease Society of America

1992 Recipient of William Randolph Hearst Award

Society Memberships:

American Academy of Neurology

Child Neurology Society

Society for Neuroscience


B. Selected peer-reviewed publications (in chronological order)

Dure LS IV, Schrader, WT, O'Malley, BW: Covalent attachment of a progestational steroid to chick oviduct progesterone receptor by photoaffinity labeling. Nature 283:784-786, 1980.

Dure L, Percy, A, Cheek, W, Laurent, J: Type I Arnold-Chiari Malformation in Children. Journal of Pediatrics 1989; 115 (4):573-576.

Albin RL, Makowiec RL, Hollingsworth Z, Dure LS IV, Penney JB, Young AB: Excitatory amino acid binding sites in the periaqueductal gray of the rat. Neuroscience Letters 1990; 118:112-115.

Albin RL, Makowiec RL, Hollingsworth Z, Dure IV LS, Penney JB, Young AB: Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic analysis. Neuroscience 1992; 46:35-48.

Dure IV LS, Young AB, Penney JB: Excitatory amino acid binding sites in Huntington's disease caudate nucleus and frontal cortex. Annals of Neurology 1991; 30:785-793.

Albin RL, Makowiec RL, Hollingsworth Z, Sakurai SY, Dure IV LS, Penney JB, Young AB: Excitatory amino acidergic pathways and receptors in the basal ganglia. Amino Acids 1991; 1:339-350.

Dure IV LS, Young AB, Penney JB: Compartmentalization of excitatory amino acid receptors in human striatum. Proceedings of the National Academy of Science USA 1992; 89:7688-7692.

Albin RL, Reiner A, Anderson KD, Dure LS, Handelin B, Balfour R, Whetsell WO, Penney JB, Young AB: Preferential loss of striato-external pallidal and striato-nigral projection neurons in presymptomatic Huntington's disease. Annals of Neurology 1992; 31:425-430.

Duyao MP, Ambrose CM, Myers RH, Novelletto A, Persichetti F, Frontali M, Folstein SE, Ross C, Franz ML, Abbott M, Gray J, Conneally PM, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini AM, Falek A, Koroshetz W, Bird E, Vonsattel JP, Bonilla E, Alvir J, Bickham-Condé J, Cha J-H, Dure L, Gomez F, Ramos M, Sanchez-Ramos J, Snodgrass SR, de Young M, Wexler NS, Barnes G, Srinidhi J, MacDonald ME, Gusella JF: Trinucleotide repeat length: instability and age of onset in Huntington's disease. Nature Genetics 1993;4:387-392.

MacDonald ME, Barnes G, Srinidhi J, Duyao MP, Ambrose CM, Myers RH, Gray J, Conneally PM, Young A, Penney J, Hollingsworth Z, Koroshetz W, Bird E, Vonsattel JP, Bonilla E, Alvir J, Bickham-Condé J, Cha JH, Dure L, Gomez F, Ramos-Arroyo M, Sanchez-Ramos J, Snodgrass SR, de Young M, Wexler NS, Moscowitz C, Penchaszadeh G, Brzustowicz L, MacFarlane H, Anderson MA, Jenkins B, Gusella JF: Gametic but not somatic instability of CAG repeat length in Huntington's disease. Journal of Medical Genetics 1993;30:982-986.

Cha J-HJ, Dure IV LS: Trinucleotide repeats in neurologic disease: an hypothesis concerning the pathogenesis of Huntington's disease, Kennedy's disease, and spinocerebellar ataxia type 1. Life Sciences 1994;54:1459-1464.

Landwehrmeyer GB, McNeil SM, Dure IV LS, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, de Young M, Avila-Gonzales AJ, Wexler NS, Difiglia M, Gusella JF, MacDonald M, Penney JB, Young AB, Vonsattel J-P: Huntington's disease gene: Expression in brain of normal and affected individuals. Annals of Neurology 1995;37:218-230.

Dure IV LS, Landwehrmeyer GB, Golden J, McNeil SM, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Difiglia M, Gusella JF, MacDonald ME, Penney JB, Young AB, Vonsattel J-P: IT15 gene expression in fetal human brain. Developmental Brain Research 1994;659:33-41.

Dure IV LS, Wiess S, Standaert DG, Rudolph G, Testa CM, Young AB: DNA fragmentation in relation to c-fos mRNA expression in rat striatum following quinolinic acid administration. Experimental Neurology 1995;133:207-214.


Book Chapters:

Albin RL, Hollingsworth Z, Sakurai SY, Makowiec RL, Higgins DS, Dure LS, Penney JB, Young AB: Excitatory amino acid binding sites in the basal ganglia, primary visual cortex, and spinal cord. In: Excitatory Amino Acids, (RP Simon, ed.). Theime Medical Publishers, Inc., pp 179-182, 1992.

Dure LS and Young AB: The distribution of glutamate receptor subtypes in mammalian central nervous system using quantitative in vitro autoradiography. In: Glutamate, (TW Stone, ed.). CRC Press, Inc., 1996.

C. Research Support

Shoulson (PI) Percy (Site PI) 9/30/02-6/30/07

NIH

Prospective Huntington At Risk Observational Study

The major goal is to characterize by prospective methods, the critical period marking the transition from health to illness in individuals who carry the Huntington disease gene, and to determine the rate of transition.

Leckman (PI) Dure (Site PI) 9/27/02-8/31/06

NIH

A Prospective Longitudinal Study of PANDAS (High-Low study)

This study is an observational study of the possible relationship between Tourette syndrome, OCD and Strep infections. There is no overlap.

Aileen Shinaman (PI) Dure (Site PI) 04/01/05 - 01/31/08

Amarin Neurosciences/Huntington's Study Group

A Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA ( Miraxion) in Patients with Mild to Moderate Huntington's Disease. (TREND-HD)

Merit Cudkowicz (PI) Dure (Site PI)

Huntington's Study Group

A Multi-Center, Double Blind, Pilot Study of Minocycline in Subjects with Huntington;s Disease (DOMINO)

Shoulson (PI) Dure (Site PI)

High Q Foundation/ HP Therapeutics/ Huntington's Study Group

Cooperative Huntington's Disease Observational Research Trial (COHORT)

Ira Shoulson, MD CM (PI) Dure (Site PI)

Amarin Neuroscience Ltd

A Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Trila of Ethyl-EPA (Miraxion) in Subjects with Mild to Moderate Huntington's Disease. (TREND-HD)

Completed Research Support

Kurlan (PI) Dure (Site PI) 9/25/01-7/31/05

NIH

PANDAS and Strep Infection: Are they linked? (PANDAS-Epi study)

This study is an observational study of the possible relationship between Tourette syndrome, OCD and Strep infections.

FD-R-001671-01 Marshall (PI) Dure (site PI) 9/01/99-8/31/00

FDA

Riluzole Dosing in Huntington Disease "RID-HD"

The major goal was to determine the safety and efficacy of riluzole for the treatment of chorea in adults with Huntington disease.

FD-R-001111-04 Sallee (PI) Dure (Co PI) 4/1/01-3/31/02

FDA

Multisite Study of Pergolide in Children with Tourette Syndrome

The major goal is to establish safety and efficacy of pergolide for the treatment of children with Tourette syndrome.

Dure (PI) 4/2/02-9/30/08

Eli Lilly and Company

Long-Term, Open Label, Safety Study of Tomoxetine HCl in Patients 6 Years and Older

The major goal is to follow subjects with ADHD and Tourette syndrome long term on open label tomoxetine.

Dure (PI) 6/1/01-5/31/03

Eli Lilly and Company

A Randomized, Double Blind Study of Tomoxetine HCl in Pediatric Outpatients with ADHD and Comorbid Tic Disorders

The major goal is to determine the efficacy and safety of tomoxetine in the treatment of ADHD in children with Tourette syndrome.

Dure (PI) 1/8/01-1/2/03

Eli Lilly and Company

A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Olanzapine in the Treatment of Motor, Psychological and Cognitive Abnormalities in Outpatients with Huntington Disease

The major goal is to establish the safety and efficacy of olanzapine for the treatment of chorea in adults with Huntington disease.